Azithromycin

AZIVIB 250| 500 & JEMAZI 250|500

COMPOSITON
AZITHROMYCIN250 MG500 MG200 MG
SPECIFICATION
FORMTABLETTABLETPEDIATRIC
PACKING10X610X330ML
PACKING TYPEBLISTERBLISTER
MRP643.7 | 650649.4 | 65093.7

ALSO AVAILABLE

DESCRIPTION

Azithromycin is a semi-synthetic macrolide antibiotic of the azalide class. Like other macrolide antibiotics, azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of the bacterial 70S ribosome. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the process of translation. Its effects may be bacteriostatic or bactericidal depending of the organism and the drug concentration. Its long half life, which enables once daily dosing and shorter administration durations, is a property distinct from other macrolides.

SIDE EFFECTS

Potentially serious side effects of angioedema and cholestatic jaundice were reported.

INDICATION

For the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions:

H. influenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae, M. pneumoniae, S. pyogenes, S. aureus, S. agal.